Drugs / MS-275
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00185302 | Dec 2004 → Jul 2006 | melanoma | Bayer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MS-275 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00185302 ↗ |
| Known as | BAY 86-5274 | “Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)” NCT00185302 ↗ |
| Known as | ZK 244894 | “Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)” NCT00185302 ↗ |
| Action | Inhibit | “Histone Deacetylase Inhibitor” NCT00185302 ↗ |
| Route | Oral | “MS-275 orally” NCT00185302 ↗ |